- Raised $30M funding round led by Columbus Venture Partners, Jan 2025
- Raised $5M funding round led by California Institute of Regenerative Medicine (CIRM), Oct 2022
- Raised $5.7M funding round, Mar 2020
About
Lutris Pharma is developing the topical B-Raf inhibitor LUT014, a proprietary small molecule allowing administration of epidermal growth factor receptor (EGFR) inhibitors to patients without the interruptions caused by typical cutaneous side effects. Leveraging the paradoxical effect of B-Raf inhibitors, LUT014 decreases dermal toxicities associated with EGFR inhibitors, thus reducing acneiform lesions associated with such therapy. The technology is based on the paradoxical effect of B-Raf inhibitors on wild-type epithelial cells, thus overriding MAP kinase pathway inhibition. By reversing the inhibitory effect of EGFR inhibitors on downstream proteins in the skin cells, LUT014 reduces dose-limiting acneiform lesions associated with EGFR inhibitors. Following FDA approval of IND, Lutris initiated a phase-1 study of the safety, tolerability, pharmacokinetics, and preliminary efficacy of LUT014 topically applied once a day for four weeks in metastatic colorectal cancer patients with EGFR inhibitor-induced acneiform lesions. Lutris Pharma was established with a vision of improving the effectiveness of anticancer therapy as well as the quality of life for patients being treated with EGFR inhibitors.
Funding history · 4 rounds · $45.7M total
Q&A
- What is Lutris Pharma's primary focus?
- Lutris Pharma is developing LUT014, a topical B-Raf inhibitor designed to allow patients to continue epidermal growth factor receptor (EGFR) inhibitor anticancer therapy without interruptions caused by cutaneous side effects like acneiform lesions.
- When was Lutris Pharma founded?
- Lutris Pharma was founded in December 2015.
- How many employees does Lutris Pharma have?
- Lutris Pharma has 1-10 employees.
- What is the total amount of funding Lutris Pharma has raised to date?
- Lutris Pharma has raised a total of $45,690,000 USD.
- Which investors participated in Lutris Pharma's January 2025 funding round?
- In January 2025, Lutris Pharma secured a private funding round with participation from.
- What is the status of Lutris Pharma's lead product, LUT014?
- Following FDA IND approval, Lutris Pharma initiated a phase-1 study for LUT014 to evaluate its safety, tolerability, pharmacokinetics, and preliminary efficacy in metastatic colorectal cancer patients with EGFR inhibitor-induced acneiform lesions.
- Who is the CEO of Lutris Pharma?
- Noa Shelach is the CEO of Lutris Pharma.
- What type of company is Lutris Pharma classified as?
- Lutris Pharma is classified as a startup in the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | lutris-pharma.com |
|---|---|
| linkedin.com/company/79633164 |
Identifiers & details
| Founded | 2015-12 |
|---|---|
| Employees (exact) | 6 |
Radar intelligence
Patents
| EPO | 5 |
|---|
Web history (Wayback)
| Domain | lutris-pharma.com |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|